Bevifimod

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameBevifimod
Drug Alias NameSPAStaphylococcal protein A (Protalex)PRTX-001PRTX-100
ClassificationNatural product/Extract > Microbial extractBiologics
Mechanisms of ActionMacrophages inhibitorsImmunoglobulin replacements
TargetsImmunoglobulin
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProtalex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProtalex Inc
Active IndicationsN/A
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank